Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
- PMID: 20737576
- PMCID: PMC4332768
- DOI: 10.1002/cncr.25354
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
Abstract
Background: Results from salvage therapy in adult patients with acute lymphocytic leukemia (ALL) are wide-ranging and depend on several disease and patient characteristics. The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics.
Methods: Adults with ALL who had primary resistance to frontline therapy or who had a disease recurrence after a first complete response (CR) duration <1 year were analyzed. Multivariate analyses for subsequent CR and survival were conducted.
Results: Seventy-five of 245 patients (31%) achieved CR. The median CR duration was 5 months, the median survival was 4.7 months. In multivariate analysis, independent poor prognostic factors for not achieving CR were age >55 years, bone marrow blasts ≥20%, and platelet count <75 × 10(9) /L. Variables that were associated independently with shorter survival were age >55 years, bone marrow blasts ≥20%, platelet count <75 × 10(9) /L, albumin level <3 g/L, and lactic dehydrogenase level ≥1000 IU/L. Patients who had ≥3 of the 5 adverse factors (45%) had a median survival of 2 to 3 months and CR rates of 8% to 15%. Achieving CR was associated independently with improved survival in a landmark multivariate analysis (P < .0001; hazard ratio, 0.40; 95% confidence interval, 0.03-0.72).
Conclusions: The current analyses identified a subset of adults patients ALL in first salvage for whom standard therapies were associated with an extremely poor outcome. The results also confirmed the importance of achieving CR to attain improved survival.
Copyright © 2010 American Cancer Society.
Conflict of interest statement
CONFLICT OF INTEREST DISCLOSURES
The authors made no disclosures.
Figures
Similar articles
-
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.Cancer. 2008 Dec 1;113(11):3186-91. doi: 10.1002/cncr.23919. Cancer. 2008. PMID: 18846563 Free PMC article.
-
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.Cancer. 1999 Oct 1;86(7):1216-30. doi: 10.1002/(sici)1097-0142(19991001)86:7<1216::aid-cncr17>3.0.co;2-o. Cancer. 1999. PMID: 10506707 Clinical Trial.
-
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.Leuk Lymphoma. 2010 Mar;51(3):475-80. doi: 10.3109/10428190903503412. Epub 2010 Jan 18. Leuk Lymphoma. 2010. PMID: 20078325 Free PMC article.
-
Outcome of patients with acute myelogenous leukemia after second salvage therapy.Cancer. 2005 Aug 1;104(3):547-54. doi: 10.1002/cncr.21187. Cancer. 2005. PMID: 15973664
-
Adult acute leukemia.Curr Probl Cancer. 1997 Jan-Feb;21(1):1-64. doi: 10.1016/s0147-0272(97)80006-2. Curr Probl Cancer. 1997. PMID: 9058027 Review.
Cited by
-
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.Haematologica. 2024 May 1;109(5):1385-1392. doi: 10.3324/haematol.2023.284310. Haematologica. 2024. PMID: 38058184 Free PMC article.
-
Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies.Expert Opin Biol Ther. 2015 Jun;15(6):895-908. doi: 10.1517/14712598.2015.1041912. Expert Opin Biol Ther. 2015. PMID: 25985814 Free PMC article. Review.
-
Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.Cancer Med. 2021 Apr;10(8):2601-2610. doi: 10.1002/cam4.3731. Epub 2021 Mar 18. Cancer Med. 2021. PMID: 33734596 Free PMC article.
-
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19. Blood. 2015. PMID: 26480933 Free PMC article.
-
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.Adv Ther. 2017 Jan;34(1):148-155. doi: 10.1007/s12325-016-0447-x. Epub 2016 Nov 21. Adv Ther. 2017. PMID: 27873237 Free PMC article. Clinical Trial.
References
-
- Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605–615. - PubMed
-
- Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671. - PubMed
-
- Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–2801. - PubMed
-
- Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337–1354. - PubMed
-
- Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000;14:1367–1379. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources